Acute study of clinical effectiveness of nesiritide in decompensated heart failure: Nesiritide redux

Current Heart Failure Reports

Volumn 8, Issue 3, 2011, Pages 226-232

  Pleister, Adam P ^a   Baliga, Ragavendra R ^a   Haas, Garrie J ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Acute decompensated heart failure; ASCEND HF; Dyspnea; Evidence based guidelines; Heart failure; Hospital readmission; Hypertension; Hypotension; Mortality; Nesiritide; Randomized controlled trial; Renal dysfunction

Indexed keywords

DOBUTAMINE; GLYCERYL TRINITRATE; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; PLACEBO;

ACUTE HEART FAILURE; ARTICLE; DEATH; DRUG EFFICACY; DYSPNEA; HOSPITAL READMISSION; HUMAN; HYPOTENSION; PROSPECTIVE STUDY; PULMONARY ARTERY OCCLUSION PRESSURE; TREATMENT OUTCOME;

ADULT; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HEART FAILURE; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PATIENT SELECTION; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 80055060618     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-011-0066-4     Document Type: Article

References (54)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
2. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000;83:596-602. (Pubitemid 30316742)
3. Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation. 2006;113:1693-1701.
4. Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4:361-371. (Pubitemid 35190362)
5. Adams Jr KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216. (Pubitemid 40348525)
6. Fonarow GC, Adams Jr KF, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-580. (Pubitemid 40171239)
7. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27:2725-2736. (Pubitemid 44729876)
8. Kosiborod M, Lichtman JH, Heidenreich PA, et al. National trends in outcomes among elderly patients with heart failure. Am J Med. 2006;119:616-617.
9. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
10. Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med. 2005;353:2788-2796. (Pubitemid 43016818)
11. Felker GM, Adams KF, Konstam MA, et al. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J. 2003;145:S18-S25. (Pubitemid 36207921)
12. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840-847.
13. Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;41:565-571. (Pubitemid 36223320)
14. Ramírez A, Abelmann WH. Cardiac decompensation. N Engl J Med. 1974;290:499-501.
15. Di Somma S, Magrini L, Ferri E. In-hospital brain natriuretic peptide and N-terminal prohormone brain natriuretic peptide variations are predictors of short-term and long-term outcome in acute decompensated heart failure. Crit Care. 2011; 15(1):116.
16. Lam LL, Cameron PA, Schneider HG, et al. Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting. Ann Intern Med. 2010;153(11):728-735.
17. Di Somma S, Magrini L, Pittoni V, et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Crit Care. 2010;14(3):R116.
18. Palazzuoli A, Gallotta M, Quatrini I, et al. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010;6:411-418.
19. Burger AJ. A review of the renal and neurohormonal effects of Btype natriuretic peptide. Congest Heart Fail. 2005;11(1):30-38.
20. Kasama S, Toyama T, Kumakura H, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure. J Nucl Med. 2004;45(7):1108-1113. (Pubitemid 47611655)
21. Cheng JW. Nesiritide: review of clinical pharmacology and role in heart failure management. Heart Dis. 2002;4(3):199-203. (Pubitemid 34670488)
22. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebocontrolled, randomized crossover trial. Circulation. 1996;94:3184-3189. (Pubitemid 26427485)
23. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-253. (Pubitemid 30490392)
24. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF): Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
25. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905. 26. (Pubitemid 40548187)
26. Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J. 2006;152:1084-1090. (Pubitemid 44854791)
27. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491. (Pubitemid 40470642)
28. The Pink Sheet FDC Reports. Chevy Chase, MD. 2005;67(17):3.
29. Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol. 2001;88:35-39. (Pubitemid 32553889)
30. Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798-803. (Pubitemid 34185326)
31. Mentzer RM, Oz MC, Sladen RN, et al. Effect of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery. J Am Coll Cardiol. 2007;49:716-726. (Pubitemid 46205038)
32. Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail. 2008;1(1):9-16.
33. Yancy CW, Krum H, Massie BM, et al. The second follow-up serial infusions of nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. Am Heart J. 2007;153 (4):478-484. (Pubitemid 46442809)
34. Yancy CW, Singh A. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial). Am J Cardiol. 2006;98(2):226-229. (Pubitemid 43975501)
35. Yancy CW. Treatment with B-type natriuretic peptide for chronic decompensated heart failure: insights learned from the follow-up serial infusion of nesiritide (FUSION) trial. Heart Fail Rev. 2004;9 (3):209-216. (Pubitemid 40521283)
36. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol. 2004;94(5):595-601. (Pubitemid 39165837)
37. LeLorier J, Grégoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large, randomized, controlled trials. N Engl J Med. 1997;337:536-542. (Pubitemid 27352021)
38. Panel of Cardiology Experts Provides Recommendations to Scios Regarding NATRECOR [press release]. Fremont, CA; June 13, 2005.
39. Hernandez AF, O'Connor CM, Starling RC, et al. Rationale and design of the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure Trial (ASCENDHF). Am Heart J. 2009;157:271-277.
40. Ezekowitz JA, Hernandez AF, Starling RC, et al. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND- HF). Am Heart J. 2009;157:219-228.
41. Armstrong PW, Rouleau JL. A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial. Can J Cardiol. 2008;24(Suppl B):30B-32B.
42. Hernandez AF (2010) Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) - nesiritide or placebo for improved symptoms and outcomes in acute decompensated HF. American Heart Association 2010 Scientific Sessions, November 14, 2010, Chicago, IL (Late- Breaking Clinical Trials I).
43. Gensch C, Hoppe U, Bohm M, et al. Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010. Clin Res Cardiol. 2011;100:1-9.
44. Abraham WT, Trupp RJ, Jarjoura D. Nesiritide in acute decompensated heart failure: a pooled analysis of randomized controlled trials. Clin Cardiol. 2010; 33(8):484-489.
45. Chow SL, O'Barr SA, Peng J, et al. Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure. J Card Fail. 2011; 17(3):181-187.
46. Fonarow GC. Nesiritide: practical guide to its safe and effective use. Rev Cardiovasc Med. 2001;2 Suppl 2:S32.
47. Mills RM, Hobbs RE. How to use nesiritide in treating decompensated heart failure. Cleve Clin J Med. 2002;69:252-256. (Pubitemid 34228961)
48. The Pink Sheet FDC Reports. Chevy Chase, MD. 2005;67(29):9.
49. Nesiritide for decompensated congestive heart failure. Med Lett Drugs Ther. 2001;43:100-101.
50. Chen HH, Sundt TM, Cook DJ, et al. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation. 2007;116:I-134-I-138.
51. Riter HG, Redfield MM, Burnett JC, et al. Nonhypotensive lowdose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol. 2006;47:2334-2335. (Pubitemid 43795074)
52. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620-1625. (Pubitemid 39297985)
53. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steadystate infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37-44. (Pubitemid 28252539)
54. Lisy O, Huntley BK, McCormick DJ, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52:60-68. (Pubitemid 351852935)